Vectibix®

You are now leaving vectibix.co.uk
Amgen does not endorse or accept liability for sites controlled by third parties

You are now leaving vectibix.co.uk
Amgen does not endorse or accept liability for sites controlled by third parties

You are now leaving vectibix.co.uk
Amgen does not endorse or accept liability for sites controlled by third parties

Return to Previous Page Continue

Links to prescribing information and adverse event reporting information can be found at the bottom of the page. For UK Healthcare professionals only.
GB SmPC|NI SmPC

What is Vectibix®?
Vectibix® (panitumumab) is a fully human monoclonal anti-EGFR antibody for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).1 It is recommended by NICE for previously untreated RAS wild-type mCRC in adults in combination with FOLFOX or FOLFIRI.2
Clinical evaluation

Capacity evaluations

Discover how Vectibix has demonstrated potential capacity savings in NHS trust service evaluations compared with cetuximab.3–5
MORE
Resources

Resources

Access helpful information for you and your patients.
MORE
Request support
Get in touch with the Amgen team who will assist with your enquiry.
GO

References

  1. Vectibix® (panitumumab) Summary of Product Characteristics.
  2. NICE. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA349).
  3. Cortez L, Neill W, Southam S. A Service evaluation of capacity use (chair and treatment time) for metastatic colorectal cancer patients (mCRC) treated with EGFR therapies and chemotherapy at The Royal Marsden NHS Foundation Trust. J Oncol Pharm Practice. 2022;28:40–1(suppl 2). Abstract 43.
  4. Case, A. & Arif, S. (2019). Annals of Oncology. 30(Supplement 4).
  5. Case A, Adams, Arif S. Presentation at ESMO 21st World Congress on Gastrointestinal Caner, 3-6 July 2019.